Background Type I interferons (IFNs) appear to play a central role in disease pathogenesis
in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods …

Objective To evaluate the safety and tolerability of multiple intravenous (IV) doses of
sifalimumab in adults with moderate‐to‐severe systemic lupus erythematosus (SLE) …

Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb,
randomised, double-blind, placebo-controlled study (NCT01283139) of adults with …

Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …

Chronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus
erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the …

Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …

Previous reports have described the appearance of systemic lupus erythematosus (SLE)
cases following interferon-α (IFN-α) therapy, IFN-regulated gene expression is significantly …

Objective To investigate long‐term safety and tolerability of anifrolumab, a human
monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with …

Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …

Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …